Jeffrey Colnes, MD
Cardiovascular Disease · York, MENPI 1649204504
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Abbott at 41.8% of the total. Reporting peaked in 2019 at $5,510 and has fallen 80.2% since, to $1,091 in 2025. Among cardiovascular disease clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 271 payments — averaging $79.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$9K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$7K
- Medtronic$1K
- Abiomed$570
- Boston Scientific$520
- Johnson & Johnson$347
- plus $3K from 24 others
What the payments were for
- Speaking & faculty fees$6,00028%
- Travel & lodging$4,09819%
- Food & beverage$11,45153%
- Education$1251%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 90 | $9,067 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 39 | $7,023 |
| Medtronic(2 entities) | 25 | $1,360 |
| Abiomed | 14 | $570 |
| Boston Scientific | 8 | $520 |
| Johnson & Johnson | 15 | $347 |
| E.r. Squibb & Sons, L.L.C. | 20 | $339 |
| Novartis | 12 | $279 |
| Lantheus Medical Imaging, Inc. | 2 | $213 |
| AstraZeneca | 9 | $201 |
| Shockwave Medical, Inc | 1 | $193 |
| Pfizer | 9 | $186 |
| Stryker | 1 | $176 |
| Sanofi-aventis U.S. LLC | 2 | $166 |
| Elutia, Inc. | 1 | $148 |
| Cardiovascular Systems Inc. | 1 | $146 |
| Actelion Pharmaceuticals US, Inc. | 4 | $121 |
| Bayer | 2 | $120 |
| Atricure, Inc. | 1 | $107 |
| Amgen | 5 | $100 |
| Livanova USA, Inc. | 1 | $93 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $28 |
| Cvrx, Inc. | 1 | $28 |
| Edwards Lifesciences | 1 | $25 |
| AbbVie | 1 | $23 |
| Penumbra, Inc. | 1 | $22 |
| Cardinal Health 200 LLC | 1 | $20 |
| Boehringer Ingelheim | 1 | $19 |
| Smith+Nephew | 1 | $18 |
| Biotronik Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$6,147
- AVEIR$4,834
- Confirm Rx$582
- Watchman$365
- Mosaic$258
- Micra$252
- Quadra Assura CRT Defibrillator$251
- XARELTO$240
- MitraClip$194
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$193
- FLOWTRIEVER CATHETER, S$176
- CT THROMBECTOMY SYSTEM KIT$176
- ECM Patch,Pouch$148
- CARDIOMEMS$148
- Optis Coronary Imaging System$147
- Diamondback Coronary$146
- Impella$142
- DRAGONFLY OPSTAR$135
- Definity$132
- JOT DX$131
How this compares
$21,674 in reported general payments places this provider in the 95th percentile of 99 cardiovascular disease providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 391 | $492,214 |
| EntrestoSacubitril/Valsartan | 99 | $136,377 |
| XareltoRivaroxaban | 66 | $89,651 |
| JardianceEmpagliflozin | 61 | $69,846 |
| FarxigaDapagliflozin Propanediol | 43 | $47,048 |
| VascepaIcosapent Ethyl | 43 | $42,313 |
| Repatha SureclickEvolocumab | 45 | $38,119 |
| BrilintaTicagrelor | 19 | $18,719 |
| Repatha SyringeEvolocumab | 11 | $18,047 |
| Dofetilide | 17 | $9,876 |
| Atorvastatin Calcium | 604 | $7,513 |
| Metoprolol Succinate | 373 | $5,482 |
| Rosuvastatin Calcium | 120 | $3,229 |
| Amiodarone Hcl | 130 | $2,937 |
| Amlodipine Besylate | 282 | $2,475 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $186 | $492,214391 claims |
| NovartisEntresto | $279 | $136,37799 claims |
| Johnson & JohnsonXarelto | $347 | $89,65166 claims |
| Boehringer IngelheimJardiance | $19 | $69,84661 claims |
| AstraZenecaFarxiga, Brilinta | $201 | $65,76862 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 99 cardiovascular disease providers in Maine.
Other cardiovascular disease in York
- Lawrence PetrovichYork$1K
- Alan HymansonYork$748
- Ronald RosenfeldPerry$51K
- Jonathan HalevyAugusta$22K
- Howard GlassWestbrook$13K
- Jaidip ChakravarttiScarborough$8K
- Adam KarpmanPortland$7K
- Marco DiazScarborough$6K
- Bram GellerPortland$5K
- Gemini YesodharanLewiston$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.